Somewhat Positive Media Coverage Somewhat Unlikely to Impact Tokai Pharmaceuticals (NVUS) Share Price

News stories about Tokai Pharmaceuticals (NASDAQ:NVUS) have been trending somewhat positive recently, according to Accern. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Tokai Pharmaceuticals earned a daily sentiment score of 0.04 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 45.939660693051 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Tokai Pharmaceuticals (NVUS) opened at 4.82 on Friday. The company’s market cap is $33.47 million. The stock has a 50 day moving average of $4.13 and a 200-day moving average of $5.60. Tokai Pharmaceuticals has a 52-week low of $3.42 and a 52-week high of $18.81.

Separately, Zacks Investment Research raised shares of Tokai Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, July 12th.

TRADEMARK VIOLATION NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Tokai Pharmaceuticals (NVUS) Share Price” was originally published by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://transcriptdaily.com/2017/10/08/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-tokai-pharmaceuticals-nvus-share-price.html.

Tokai Pharmaceuticals Company Profile

Novus Therapeutics, Inc, formerly Tokai Pharmaceuticals, Inc, is a pharmaceutical company. The Company is focused on the acquisition, development, and commercialization of ear, nose, and throat products. It has two platforms: OP-01 Foam Platform and OP-02 Surfactant Program. OP-01 is developed with the intent to be used as a delivery vehicle for drugs treating ears, as well as the nasal and sinus cavities.

Insider Buying and Selling by Quarter for Tokai Pharmaceuticals (NASDAQ:NVUS)

Receive News & Ratings for Tokai Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tokai Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply